Edwards’ latest-generation balloon-expandable transcatheter heart valve incorporates a proprietary calcification-resistant tissue technology
The medicine was well tolerated, with no unexpected safety issue
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
The three-day expo will feature an expansive exhibition showcasing MSMEs, startups, research institutions, future innovation pavilions, state showcases, and government initiatives
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
Subscribe To Our Newsletter & Stay Updated
